Journal of Antibiotics

(The H4-Index of Journal of Antibiotics is 20. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 500 papers]. The publications cover those that have been published in the past four years, i.e., from 2019-11-01 to 2023-11-01.)
Ivermectin: a systematic review from antiviral effects to COVID-19 complementary regimen214
Antibiotics in the clinical pipeline in October 2019175
Psilocybin: from ancient magic to modern medicine56
Recent progress in biodiversity research on the Xylariales and their secondary metabolism52
Industry incentives and antibiotic resistance: an introduction to the antibiotic susceptibility bonus45
Antifungal peptides produced by actinomycetes and their biological activities against plant diseases36
Highlights of marine natural products having parallel scaffolds found from marine-derived bacteria, sponges, and tunicates33
Chlorinated bis-indole alkaloids from deep-sea derived Streptomyces sp. SCSIO 11791 with antibacterial and cytotoxic activities33
Bioactive small secondary metabolites from the mushrooms Lentinula edodes and Flammulina velutipes30
Ferrocenyl chalcone derivatives as possible antimicrobial agents29
Application of Mycobacterium smegmatis as a surrogate to evaluate drug leads against Mycobacterium tuberculosis29
Possible drugs for the treatment of bacterial infections in the future: anti-virulence drugs26
Thiopeptides: antibiotics with unique chemical structures and diverse biological activities26
The mechanisms of action of ivermectin against SARS-CoV-2—an extensive review26
Chryseobacterium antibioticum sp. nov. with antimicrobial activity against Gram-negative bacteria, isolated from Arctic soil25
Antimicrobial and antibiofilm activities of ursolic acid against carbapenem-resistant Klebsiella pneumoniae25
Antibiotic repurposing: bis-catechol- and mixed ligand (bis-catechol-mono-hydroxamate)-teicoplanin conjugates are active against multidrug resistant Acinetobacter baumannii22
Sealutomicins, new enediyne antibiotics from the deep-sea actinomycete Nonomuraea sp. MM565M-173N221
Targeting hypoxia-inducible factor 1 (HIF-1) signaling with natural products toward cancer chemotherapy21
Discovery of fingolimod based on the chemical modification of a natural product from the fungus, Isaria sinclairii21
Rifamycin antibiotics and the mechanisms of their failure20